| Literature DB >> 10955236 |
K Yamaguchi1, S Miyazaki, F Kashitani, M Iwata, M Kanda, Y Tsujio, J Okada, Y Tazawa, N Watanabe, N Uehara, J Igari, T Oguri, M Kaimori, C Kawamura, Y Iinuma, T Nisawataira, H Tashiro, K Ueno, S Ishigo, M Yasujima, S Kawahara, C Itoh, T Yoshida, K Yamanaka, S Toyoshima, J Katoh, M Kudoh, T Matsushima, Y Niki, N Miyashita, T Funato, M Kaku, N Sato, Y Saito, K Ishii, M Kuwabara, T Hongo, K Negayama, S Kamihira, Y Miyazaki, M Takii, M Ishii, K Nakagawa, J Ono, T Takada, N Murakami, M Taira, I Tamaki, Y Matsudou, I Nakasone.
Abstract
The surveillance study was conducted to determine the antimicrobial activity of fluoroquinolones (ofloxacin, levofloxacin, ciprofloxacin, tosufloxacin) and other 20 antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. The resistance to fluoroquinolones was remarkable in Enterococci, methicillin-resistant staphylococci and Pseudomonas aeruginosa from UTI. However, many of the common pathogens such as Streptococcus pneumoniae including penicillin-resistant isolates, methicillin-susceptible Stahylococcus aureus, Moraxella catarrhalis, the family of Enterobacteriaceae, Haemophilus influenzae including ampicillin-resistant isolates have been kept to be susceptible to fluoroquinolones. About 90% of P. aeruginosa isolates from RTI were susceptible to fluoroquinolones. In conclusion, the results from this surveillance study suggest that fluoroquinolones are useful in the treatment of various bacterial infections including respiratory infections.Entities:
Mesh：
Substances：
Year: 2000 PMID： 10955236
Source DB: PubMed Journal: Jpn J Antibiot ISSN： 0368-2781